Cooper Companies reported Q3 adjusted EPS of $1.15, beating estimates by 3.6%, but revenues of $1.066 billion missed expectations by 3.0%. CooperVision faced pressure from U.S. channel inventory reductions, while CooperSurgical showed resilience with 2% revenue growth. The stock fell 15.9% after-hours as management expects continued destocking headwinds in Q4, though underlying U.S. consumption remains healthy.

GE HealthCare Technologies has submitted its next-generation StarGuide GX digital SPECT/CT system for FDA 510(k) clearance following CE Mark approval in Europe. The system features dual-sided CZT detectors, NVIDIA RTX computing, and rapid collimator exchange, designed to support emerging radioligand therapies including alpha emitters like Actinium-225 and Lead-212. Despite the regulatory milestone, GEHC stock declined 3% following the announcement.

The Cooper Companies (COO) is scheduled to report fiscal Q3 2026 results on September 9, with consensus estimates suggesting modest 3.6% sales growth and 0.9% EPS growth. While CooperVision's premium lens portfolio and myopia control products are expected to drive growth, Asia Pacific headwinds and margin pressures from FX and tariffs present challenges. The stock carries a Zacks Rank #4 (Sell) with no conclusive earnings beat predicted.

AMN Healthcare Services expects Q3 nurse and allied staffing revenues to grow 9-11% driven by strong healthcare demand and expanding Managed Services Programs (MSPs) which now represent 46% of consolidated revenues. The company is diversifying through AI-enabled platforms and recent acquisitions. However, competitive pressures, declining language services revenues, and regulatory challenges pose risks to growth.

Nyxoah (NYXH) initiated its U.S. post-approval BREATHE study with the first patient implanted using the Genio system for obstructive sleep apnea treatment. The study will enroll up to 229 patients across 25 U.S. centers over five years to generate real-world evidence supporting physician adoption and payer reimbursement. Despite the milestone, NYXH shares fell approximately 8% following the announcement.

Philips launched the eV14-2v transvaginal transducer for gynecology and early obstetrics imaging, offering 41.7% greater penetration, 10% higher resolution, and a 22% lighter design compared to its predecessor. The FDA-cleared device integrates with Philips' Collaboration Live platform for real-time remote consultations. The global obstetrics & gynecology ultrasound market is projected to grow from $2.13 billion in 2024 to $2.84 billion by 2030 at a 4.94% CAGR.

Novocure Limited (NVCR) disclosed unauthorized access to internal systems in mid-August 2026, exposing internal patient ID numbers for over 1,400 U.S. patients and contact information for healthcare providers and employees. The company stated that medical devices were not accessed, systems remained functional, and no material financial impact is expected. NVCR shares rose 3.2% since the September 1 disclosure.

Cencora's U.S. Healthcare Solutions business demonstrated accelerating momentum with 5% revenue growth and 16% operating income growth in Q3, driven by specialty strength and OneOncology's performance. However, the company faces headwinds from manufacturer list-price reductions, the pending MWI divestiture expected to create a $150 million earnings impact, and regulatory uncertainty around 340B and ASP rules. GLP-1 growth and international operations provide diversification opportunities.

Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and expanding high-volume HDF and 5008X dialysis systems. However, the company faces significant challenges including persistent U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation-related cost risks. The company maintains a Zacks Rank #3 (Hold) with consensus 2026 earnings expected to decline 7% year-over-year.

Hims & Hers (HIMS) is driving growth through expanded weight-loss offerings, international expansion surging 17-fold, and AI-enabled care improving engagement and reducing costs. However, the company faces headwinds from gross margin compression due to lower-margin product mix, negative free cash flow from working capital requirements, and regulatory uncertainty around FDA peptide therapy approvals. The stock holds a Zacks Rank #3 (Hold) rating.

Merit Medical Systems (MMSI), a Zacks Rank #2 (Buy) company, is well-positioned for growth driven by its broad medical device portfolio, R&D investments, and the WRAPSODY renal therapy opportunity showing strong clinical outcomes. However, the company faces headwinds from tariffs expected to reduce 2026 results by $16 million (21 cents per share) and intense competition in the medical device space.

10x Genomics secured a favorable jury verdict against Parse Biosciences (a Qiagen subsidiary), winning $4.8M in damages for willful patent infringement on three single-cell analysis patents. The jury upheld all three patents' validity. 10x Genomics plans to seek enhanced damages, attorney fees, and a permanent U.S. injunction in post-trial proceedings. Despite the legal win, TXG shares fell over 5% following the announcement.